131 related articles for article (PubMed ID: 37160252)
1. How Uncertainty Matters Under Risk Neutrality.
Glynn D; Lomas J
Value Health; 2023 Aug; 26(8):1151-1154. PubMed ID: 37160252
[TBL] [Abstract][Full Text] [Related]
2. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
3. Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
McCullagh L; Walsh C; Barry M
Pharmacoeconomics; 2012 Oct; 30(10):941-59. PubMed ID: 22667458
[TBL] [Abstract][Full Text] [Related]
4. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
5. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
7. Are healthy-years equivalents an improvement over quality-adjusted life years?
Johannesson M; Pliskin JS; Weinstein MC
Med Decis Making; 1993; 13(4):281-6. PubMed ID: 8246699
[TBL] [Abstract][Full Text] [Related]
8. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
Elbasha EH
Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
[TBL] [Abstract][Full Text] [Related]
9. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
10. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
O'Brien BJ; Sculpher MJ
Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
[TBL] [Abstract][Full Text] [Related]
11. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.
McKenna C; Soares M; Claxton K; Bojke L; Griffin S; Palmer S; Spackman E
Value Health; 2015 Sep; 18(6):865-75. PubMed ID: 26409615
[TBL] [Abstract][Full Text] [Related]
12. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
13. Dangerous omissions: the consequences of ignoring decision uncertainty.
Griffin SC; Claxton KP; Palmer SJ; Sculpher MJ
Health Econ; 2011 Feb; 20(2):212-24. PubMed ID: 20091763
[TBL] [Abstract][Full Text] [Related]
14. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches.
Elbasha EH
Pharmacoeconomics; 2022 May; 40(5):497-507. PubMed ID: 35137340
[TBL] [Abstract][Full Text] [Related]
17. Scenario drafting to anticipate future developments in technology assessment.
Retèl VP; Joore MA; Linn SC; Rutgers EJ; van Harten WH
BMC Res Notes; 2012 Aug; 5():442. PubMed ID: 22894140
[TBL] [Abstract][Full Text] [Related]
18. Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?
Karnon J; Carlton J; Czoski-Murray C; Smith K
Appl Health Econ Health Policy; 2009; 7(1):1-9. PubMed ID: 19558190
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis with risk aversion.
Zivin JG
Health Econ; 2001 Sep; 10(6):499-508. PubMed ID: 11550291
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
